Znanstveni rad - Izvorni znanstveni rad
Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)
Cancer Biomarkers, 30 (2021), 1; 95-104. https://doi.org/10.3233/CBM-201497


Citirajte ovaj rad

Sirotković Skerlev, M., Plavetić, N. D., Sedlić, F., Kuna, S. K., Vrbanec, D., Belev, B. ... Kulić, A. (2021). Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers, 30. (1), 95-104. doi: 10.3233/CBM-201497

Sirotković Skerlev, Maja, et al. "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)." Cancer Biomarkers, vol. 30, br. 1, 2021, str. 95-104. https://doi.org/10.3233/CBM-201497

Sirotković Skerlev, Maja, Natalija Dedić Plavetić, Filip Sedlić, Sanja Kusačić Kuna, Damir Vrbanec, Borislav Belev, Stjepko Pleština, Zdenko Kovač i Ana Kulić. "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)." Cancer Biomarkers 30, br. 1 (2021): 95-104. https://doi.org/10.3233/CBM-201497

Sirotković Skerlev, M., et al. (2021) 'Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)', Cancer Biomarkers, 30(1), str. 95-104. doi: 10.3233/CBM-201497

Sirotković Skerlev M, Plavetić ND, Sedlić F, Kuna SK, Vrbanec D, Belev B, i sur.. Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years). Cancer Biomarkers [Internet]. 2021. [pristupljeno 28.11.2021.];30(1):95-104. doi: 10.3233/CBM-201497

M. Sirotković Skerlev, et al., "Prognostic value of circulating Bcl-2 and anti-p53 antibodies in patients with breast cancer: A long term follow-up (17.5 years)", Cancer Biomarkers, vol. 30, br. 1, str. 95-104, 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:834430. [Citirano: 28.11.2021.]

Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.